Can a Two-Drug punch shrink oral tumors before surgery?

NCT ID NCT07766889

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This phase 2 trial is testing whether giving two drugs before surgery can help people with advanced oral cavity cancer. The drugs, becotatug vedotin and pucotenlimab, are designed to attack cancer cells and boost the immune system. Participants receive three cycles of the combination, followed by surgery to remove the tumor. The study aims to see if this approach can significantly reduce the tumor before surgery, potentially improving long-term outcomes and allowing some patients to receive less intensive radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Becotatug vedotin (MRG003) plus pucotenlimab (HX008)
What this could lead to
If successful, this approach could shrink oral cavity tumors before surgery, potentially improving survival and allowing less intensive radiation afterward.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The drug combination may cause side effects, and the treatment might not improve outcomes as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms oral cavity squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital of Stomatology, Sun Yat-sen University

    Guangzhou, Guangdong, 510055, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.